Article Cited by others

MOLECULES OF THE MILLENNIUM

Delamanid: A new armor in combating drug-resistant tuberculosis

Xavier Alphienes Stanley, Lakshmanan Mageshwaran

Year : 2014| Volume: 5| Issue : 3 | Page no: 222-224

   This article has been cited by
 
1 Mycobacterial protein tyrosine kinase, PtkA phosphorylates PtpA at tyrosine residues and the mechanism is stalled by the novel series of inhibitors
Swati Jaiswal,Aditi Chatterjee,Sapna Pandey,Kiran Lata,Ranjith Kumar Gadi,Rajesh Manda,Sanjay Kumar,Maddi Sridhar Reddy,Ravishankar Ramachandran,Kishore K. Srivastava
Journal of Drug Targeting. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
André Campaniço,Rui Moreira,Francisca Lopes
European Journal of Medicinal Chemistry. 2018; 150: 525
[Pubmed]  [Google Scholar] [DOI]
3 Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona sp.
Wilmar Maarisit,Delfly B. Abdjul,Hiroyuki Yamazaki,Hajime Kato,Henki Rotinsulu,Defny S. Wewengkang,Deiske A. Sumilat,Magie M. Kapojos,Kazuyo Ukai,Michio Namikoshi
Bioorganic & Medicinal Chemistry Letters. 2017;
[Pubmed]  [Google Scholar] [DOI]
4 Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds
Guilherme Fernandes,Chung Man Chin,Jean Dos Santos
Pharmaceuticals. 2017; 10(2): 51
[Pubmed]  [Google Scholar] [DOI]
5 QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity
Marcelo N. Gomes,Rodolpho C. Braga,Edyta M. Grzelak,Bruno J. Neves,Eugene Muratov,Rui Ma,Larry L. Klein,Sanghyun Cho,Guilherme R. Oliveira,Scott G. Franzblau,Carolina Horta Andrade
European Journal of Medicinal Chemistry. 2017; 137: 126
[Pubmed]  [Google Scholar] [DOI]
6 Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study
Yesha S. Patel,Sarika Mehra
Frontiers in Microbiology. 2017; 8
[Pubmed]  [Google Scholar] [DOI]
7 Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis
Priya Singh,Rashmi Kumari,Rup Lal
Indian Journal of Microbiology. 2017; 57(4): 371
[Pubmed]  [Google Scholar] [DOI]
8 News on therapeutic management of MDR-tuberculosis: a literature review
Lucie Barthod,Jean-Guillaume Lopez,Christophe Curti,Charléric Bornet,Manon Roche,Marc Montana,Patrice Vanelle
Journal of Chemotherapy. 2017; : 1
[Pubmed]  [Google Scholar] [DOI]
9 Drug development against tuberculosis: Impact of alkaloids
Shardendu K. Mishra,Garima Tripathi,Navneet Kishore,Rakesh K. Singh,Archana Singh,Vinod K. Tiwari
European Journal of Medicinal Chemistry. 2017; 137: 504
[Pubmed]  [Google Scholar] [DOI]
10 Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance
Vahid Lohrasbi,Malihe Talebi,Abed Zahedi Bialvaei,Lanfranco Fattorini,Michel Drancourt,Mohsen Heidary,Davood Darban-Sarokhalil
Tuberculosis. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis
W. David Hong,Peter D. Gibbons,Suet C. Leung,Richard Amewu,Paul A. Stocks,Andrew Stachulski,Pedro Horta,Maria L. S. Cristiano,Alison E. Shone,Darren Moss,Alison Ardrey,Raman Sharma,Ashley J. Warman,Paul T. P. Bedingfield,Nicholas E. Fisher,Ghaith Aljayyoussi,Sally Mead,Maxine Caws,Neil G. Berry,Stephen A. Ward,Giancarlo A. Biagini,Paul M. O’Neill,Gemma L. Nixon
Journal of Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
12 Nitroimidazoles – molecular fireworks that combat a broad spectrum of infectious diseases
Chee Wei Ang,Angie M Jarrad,Matthew A. Cooper,Mark Arnold Thomas Blaskovich
Journal of Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
13 Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions
Monika Gaba,Chander Mohan
Medicinal Chemistry Research. 2016; 25(2): 173
[Pubmed]  [Google Scholar] [DOI]
14 New prodrugs against tuberculosis
Giorgia Mori,Laurent Roberto Chiarelli,Giovanna Riccardi,Maria Rosalia Pasca
Drug Discovery Today. 2016;
[Pubmed]  [Google Scholar] [DOI]
15 In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy
T. Parumasivam,J. G. Y. Chan,A. Pang,D. H. Quan,J. A. Triccas,W. J. Britton,H. K. Chan
Molecular Pharmaceutics. 2016;
[Pubmed]  [Google Scholar] [DOI]
16 Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Yu Zhou,Jiang Wang,Zhanni Gu,Shuni Wang,Wei Zhu,José Luis Aceña,Vadim A. Soloshonok,Kunisuke Izawa,Hong Liu
Chemical Reviews. 2016; 116(2): 422
[Pubmed]  [Google Scholar] [DOI]
17 The anti-tuberculosis agents under development and the challenges ahead
Deepak Kumar,Beena Negi,Diwan S Rawat
Future Medicinal Chemistry. 2015; 7(15): 1981
[Pubmed]  [Google Scholar] [DOI]
18 Bedaquiline and delamanid in tuberculosis
Susanna Esposito,Sonia Bianchini,Francesco Blasi
Expert Opinion on Pharmacotherapy. 2015; 16(15): 2319
[Pubmed]  [Google Scholar] [DOI]
19 Hit and lead criteria in drug discovery for infectious diseases of the developing world
Kei Katsuno,Jeremy N. Burrows,Ken Duncan,Rob Hooft van Huijsduijnen,Takushi Kaneko,Kiyoshi Kita,Charles E. Mowbray,Dennis Schmatz,Peter Warner,B. T. Slingsby
Nature Reviews Drug Discovery. 2015; 14(11): 751
[Pubmed]  [Google Scholar] [DOI]
20 Management of drug resistantTB in patients with HIV co-infection
Emanuele Pontali,Giovanni Sotgiu,Rosella Centis,Lia D’Ambrosio,Antonio Spanevello,Giovanni Battista Migliori
Expert Opinion on Pharmacotherapy. 2015; 16(18): 2737
[Pubmed]  [Google Scholar] [DOI]
21 Anti-Mycobacterial Nucleoside Antibiotics from a Marine-Derived Streptomyces sp. TPU1236A
Ying-Yue Bu,Hiroyuki Yamazaki,Kazuyo Ukai,Michio Namikoshi
Marine Drugs. 2014; 12(12): 6102
[Pubmed]  [Google Scholar] [DOI]

 

Read this article